PODCAST · health
Oncology's Green Light
by OncologyResearch
AI-Powered Insights into the Latest FDA Approvals for Everyday Oncology Clinicians
-
1
FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer
Explore the latest breakthroughs in treating MSI-H/dMMR metastatic colorectal cancer with immune therapies! This episode dives into the exciting world of immune checkpoint inhibitors (ICIs) like nivolumab (Opdivo) and ipilimumab (Yervoy), highlighting their significant clinical benefits for this specific patient population. Learn about the molecular characteristics of MSI-H/dMMR CRC that make it uniquely sensitive to immunotherapy. Our AI hosts will cover pivotal clinical trials, including CheckMate 8HW, which demonstrated the improved progression-free survival with the combination of nivolumab and ipilimumab compared to nivolumab alone. Discover how immunotherapy is becoming a new standard of care for MSI-H/dMMR metastatic CRC.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
Loading similar podcasts...